Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
Part of paid clinical trials in San Antonio, Texas.
- Sponsor
- OSI Pharmaceuticals
- Study ID
- NCT00072631
- Phase
- PHASE2
- Status
- Completed
Conditions
- Advanced Non Small Cell Lung Cancer
- Failed Prior Chemotherapy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tarceva (Trademark) (erlotinib HCl, OSI-774) — DRUGIntrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
Study Details
The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
Key Dates
- First listed
- Nov 7, 2003
- Start date
- Nov 5, 2003
- Status verified
- Jun 2015
- Primary completion
- Mar 14, 2007
- Completion
- Mar 14, 2007
Study Design
- Enrollment
- 43 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: 1 erlotinib
Primary Outcome Measure
Feasibility of intrapatient dose escalation of erlotinib HCI to introduce a characteristic, target rash, and evaluate the effect on objective response rate [ Time Frame: 3 years ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Institute for Drug Development Cancer Therapy and Research Center | San Antonio | Texas | 78229 | - |
Find similar trials in San Antonio, TX
Related Studies
- Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung CancerPHASE1 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAGPHASE2 · Recruiting · CellSight Technologies, Inc. · Iowa City, Iowa